Openly accessible

Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells

Wilson, George S, Hu, Zenan, Duan, Wei, Tian, Aiping, Wang, Xin M, McLeod, Duncan, Lam, Vincent, George, Jacob and Qiao, Liang 2013, Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells, Stem Cells and Development, vol. 22, no. 19, pp. 2655-2664.

Attached Files
Name Description MIMEType Size Downloads
duan-efficacyofusing-2013.pdf Published version application/pdf 811.63KB 30

Title Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells
Author(s) Wilson, George S
Hu, Zenan
Duan, Wei
Tian, Aiping
Wang, Xin M
McLeod, Duncan
Lam, Vincent
George, Jacob
Qiao, Liang
Journal name Stem Cells and Development
Volume number 22
Issue number 19
Start page 2655
End page 2664
Total pages 10
Publisher Mary Ann Liebert
Place of publication New Rochelle, NY
Publication date 2013
ISSN 1547-3287
Keyword(s) Cancer
Stem cells
Liver
Summary Recent evidence suggests that a subset of hepatocellular carcinomas (HCCs) are derived from liver cancer stem cells (LCSCs). In order to isolate and characterize LCSCs, reliable markers that are specific to these cells are required. We evaluated the efficacy of a range of cancer stem cell (CSC) markers in isolating and characterizing LCSCs. We show that the most widely used CSC markers are not specific to LCSCs. By western analysis, protein expression of the common markers showed no significant difference between HCC tumor tissues and adjacent non-cancerous liver. Further, isolation of LCSCs from common HCC cell lines using FACScan and microbeads showed no consistent marker expression pattern. We also show that LCSCs have unique subtypes. Immunohistochemistry of HCC tissues showed that different HCCs express unique combinations of LCSC markers. Quantitative real-time polymerase chain reaction analysis showed that LCSCs isolated using different markers in the same HCC phenotype had different expression profiles. Likewise, LCSCs isolated from different HCC phenotypes with the same marker also had unique expression profiles and displayed varying resistance profiles to Sorafenib. Thus, using a range of commonly used CSC markers in HCCs and cell lines, we demonstrate that currently available markers are not specific for LCSCs. LCSCs have unique subtypes that express distinctive combinations of LCSC markers and altered drug resistance profiles, making their identification problematic.
Language eng
Field of Research 111504 Pharmaceutical Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2013, Mary Ann Liebert
Persistent URL http://hdl.handle.net/10536/DRO/DU:30059553

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 26 Abstract Views, 31 File Downloads  -  Detailed Statistics
Created: Thu, 16 Jan 2014, 14:08:44 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.